Everence Capital Management’s Myriad Genetics MYGN Stock Holding History

Everence Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,280	Closed	-$364K	–	960
2024 Q3	$364K	Hold	13,280	–	–	0.02%	522
2024 Q2	$260	Hold	13,280	–	–	0.02%	589
2024 Q1	$283	Hold	13,280	–	–	0.02%	584
2023 Q4	$254K	Hold	13,280	–	–	0.02%	614
2023 Q3	$213	Hold	13,280	–	–	0.02%	649
2023 Q2	$293K	Hold	13,280	–	–	0.02%	532
2023 Q1	$308	Hold	13,280	–	–	0.03%	531
2022 Q4	$193	Hold	13,280	–	–	0.02%	699
2022 Q3	$253K	Hold	13,280	–	–	0.02%	575
2022 Q2	$241K	Hold	13,280	–	–	0.02%	586
2022 Q1	$335K	Hold	13,280	–	–	0.03%	529
2021 Q4	$367K	Hold	13,280	–	–	0.03%	526
2021 Q3	$429K	Hold	13,280	–	–	0.04%	445
2021 Q2	$406K	Hold	13,280	–	–	0.03%	460
2021 Q1	$404K	Hold	13,280	–	–	0.04%	442
2020 Q4	$263K	Hold	13,280	–	–	0.03%	560
2020 Q3	$173K	Sell	13,280 -200	-1%	-$2.53K	0.02%	605
2020 Q2	$196K	Hold	13,480	–	–	0.02%	583
2020 Q1	$193K	Hold	13,480	–	–	0.03%	523
2019 Q4	$367K	Hold	13,480	–	–	0.05%	406
2019 Q3	$386K	Hold	13,480	–	–	0.06%	341
2019 Q2	$374K	Buy	+13,480	New	+$381K	0.06%	350

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Everence Capital Management's MYGN Position: Q4 2024 in Review

Everence Capital Management sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 13,280 shares — an estimated $364K sold.

Everence Capital Management first reported a position in MYGN in Q2 2019 and held it in 22 quarters. The position peaked at $429K in Q3 2021. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

Everence Capital Management reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
Everence Capital Management sold 13,280 Myriad Genetics shares in Q4 2024, an estimated $364K.
Everence Capital Management first reported a position in Myriad Genetics in Q2 2019 and held it in 22 quarters.
Everence Capital Management's Myriad Genetics position peaked at $429K in Q3 2021.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.